TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MK0476 Study in Adult Patients With Acute Asthma (0476-322)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult Patients With Acute Asthma Attacks~Exclusion Criteria:~* Patient Has Any Known Or Suspected, Acute Or Chronic Cause For Their Pulmonary Symptoms Other Than Asthma (E.G., Copd, Chronic Heart Failure, Etc.)~* Patient Has A Smoking History (20 Cigarettes Per Day) Of More Than 15 Years~* Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or Other Severe Disease

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Placebo
- 2 (Type: EXPERIMENTAL): MK0476 7 mg injection
- 3 (Type: EXPERIMENTAL): MK0476 14 mg injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Strategies for the Delivery of IPTc

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age between 3 months and 5 years at enrolment.~2. Informed consent obtained from parents or legal guardians.~3. No current participation in another malaria intervention trial.~Exclusion Criteria:~1. Previous adverse reaction to treatment with SP or amodiaquine. If this is unknown, then a history of allergic reaction to any drug.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral total knee arthroplasty~Exclusion Criteria:~* Subjects with risks of hemorrhage~* Subjects with thromboembolic risks~* Subjects who weigh less than 40 kg~* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- DU-176b (Type: EXPERIMENTAL): DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
- enoxaparin sodium (Type: ACTIVE_COMPARATOR): enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 60 years of age~* Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study~* Have Relapsing Remitting Multiple Sclerosis (RRMS) according to the revised McDonald criteria 2005~* Have brain and/or spinal MRI with findings typical of Multiple Sclerosis (MS)~* Have disease duration for more than 12 months~* Have disease activity characterized by at least one clinical event and one or more Gadolinium-enhancing MRI lesions within the 6 months prior to randomization~* Have score of \<=5.5 on the Expanded Disability Status Scale (EDSS)~* Be willing and able to comply with the protocol for the duration of the study~* Have given written informed consent prior to any study-related procedure not part of the normal medical practice~Exclusion Criteria:~* Have any disease other than MS that could better explain his/her signs and symptoms~* Have complete transverse myelitis or bilateral optic neuritis~* Have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone \[ACTH\]), or total lymphoid irradiation~* Have received within 3 months prior to baseline any approved disease-modifying therapy for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure~* Have received within 30 days prior to baseline oral or systemic corticosteroids or ACTH~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rebif® New Formulation (IFN-beta-1a, RNF) (Type: EXPERIMENTAL): None
- Placebo/RNF (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise for Low Back Pain in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 12-13 years~* Complained of LBP in the past three months~Exclusion Criteria:~* Serious spinal pathologies or deformities (e.g. severe scoliosis, spinal tumours)~* Neurological conditions which alter motor tone~* Physical disabilities (e.g. spinal cord injuries) which prevent the child from being able to stand up on their own without an orthotic device or brace, or which prevent the child from taking part in normal physical education (PE) classes~* Any other serious co-morbidities (e.g. cancer, severe lung pathology)~* Provincial sports participants, or children who were currently following a specific training programme with a biokineticist or physiotherapist~* Current orthopaedic procedures or fractures of the spine, pelvis, lower or upper limbs

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- 1. Experimental Group (Type: EXPERIMENTAL): Exercise Intervention Group
- 2. Control Group (Type: NO_INTERVENTION): Control group - no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥40 and ≤ 80years of age~* Radiographic evidence of grade 2 or 3 osteoarthritis based on the Kellgren \& Lawrene radiographic entry criteria~* Stable osteoarthritis during 3 months~* Score of 100mm pain VAS ≤ 80mm at screening~* Score of 100mm pain VAS ≥ 50mm at baseline~* Written consent form voluntarily~Exclusion Criteria:~* Disease of spine or other Lower limb joints that could affect to evaluate the efficacy~* History of surgery or arthroscopy of the study joint within 6 months~* Trauma of study joint within 12 months~* Medication of constantly(more than 1 week) corticosteroid by oral within 3 months~* Medication of intra-articular injection within 3 months~* Diagnosed with psychical disorder, and taking medication~* History of upper gastrointestinal ulceration within 6 months~* History of upper gastrointestinal bleeding within 12 months~* Serum creatinine, ALT, AST, total bilirubin over UNL X 2.0 at screening test~* History of hypersensitivity to LAYLA, JOINS, or NSAIDs~* Participation in another clinical trials within 4 weeks~* Medication of constantly (more than 1 week) narcotic analgesics within 3 months~* Not consent about using effectual contraception method during trial~* Pregnant or lactating woman~* Investigator's judgment

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LAYLA (Type: EXPERIMENTAL): Drug : LAYLA tablet/ bid
- JOINS (Type: ACTIVE_COMPARATOR): Drug : JOINS tablet/ tid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or above~* Diagnosis of Acute Coronary Syndrome~* P2Y12 receptor blocker naïve and planning for a loading dose of P2Y12 receptor blocker~Exclusion Criteria:~* Chronic renal failure on dialysis or plan for dialysis within 1 year~* Serious hepatic disease~* Active bleeding disorder~* Contraindicated or allergic to Clopidogrel or ticagrelor~* History of intracranial bleeding~* Women who are pregnant or who are of childbearing potential who do not use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genotype guided group (Type: EXPERIMENTAL): Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin.
- Clinical guided group (Type: ACTIVE_COMPARATOR): Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent document.~* Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s.~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Females of childbearing potential if pregnant, lactating, or not using highly effective birth control measures.~* Any form of glaucoma other than open-angle glaucoma.~* Severe central vision loss in either eye.~* Chronic, recurrent, or severe inflammatory eye disease.~* Ocular trauma within the preceding 6 months.~* Ocular infection or ocular inflammation within the preceding 3 months.~* Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.~* Best-corrected visual acuity score worse than 55 letters using the Early Treatment Diabetic Retinopathy Study chart.~* Other ocular pathology (including severe dry eye) that may, in the opinion of the Investigator, preclude the administration of study product.~* Ocular surgery within the preceding 6 months.~* Ocular laser surgery within the preceding 3 months.~* Any abnormality preventing reliable applanation tonometry.~* Any other conditions, including severe illness, which could make the patient, in the opinion of the Investigator, unsuitable for the study.~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brinzolamide/Brimonidine (Type: EXPERIMENTAL): Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
- Brinzolamide (Type: ACTIVE_COMPARATOR): Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
- Brimonidine (Type: ACTIVE_COMPARATOR): Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with idiopathic PD without any known cause for Parkinsonism.~2. At least 30 years old at the time of PD diagnosis.~3. Currently being treated with:~   * an LD dosing frequency of at least four times a day~  * at least one dose of CD-LD ER daily~  * requiring a total daily LD dose of at least 400 mg~  * stable regimen for at least 4 weeks prior to Screening~4. Concomitant therapy with amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists is allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.~5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.~Exclusion Criteria:~1. Pregnant or breastfeeding~2. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.~3. Nonresponsive to LD therapy.~4. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.~5. Planning to take during participation in the clinical study: any controlled-release LD product, additional CD or benserazide, entacapone or tolcapone, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.~6. Any evidence of suicidal behavior within 6 months of entering the study.~7. Allergic or hypersensitive to to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.~8. History of or currently active psychosis.~9. Active or history of peptic ulcers or surgical procedure of the stomach, the small intestine or the large intestine.~10. Active or history of narrow-angle glaucoma.~11. History of malignant melanoma or a suspicious undiagnosed skin lesion.~12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.~13. Abnormal kidney function~14. Severe hepatic impairment.~15. Received any investigational medications during the 4 weeks prior to Screening.~16. Previously enrolled in IPX066 studies.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPX066 (Type: EXPERIMENTAL): Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing neurosurgery that require head fixation with mayfield head holder~* patients who agree to our study~Exclusion Criteria:~* patients who don't agree to our study~* BMI\<16.0 or BMI\>30~* cardiovascular disease, pulmonary disease, renal disease~* alcoholic abuser or drug abuser~* patients who takes any drug having an influence on cardiovascular system or sympathetic nervous system~* any use of local anesthetics or drugs which have an influence on cardiovascular system from beginning of induction to peri-fixation period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- neurosurgery with fixation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Garcinia Mangostana L.Pericarp Gel as a Local Drug Delivery in Treatment of Chronic Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 30 to 65 years~* Systemically healthy subjects with chronic periodontitis~Exclusion Criteria:~* aggressive periodontitis,~* systemic disorders,~* known or suspected allergy to the MGA/placebo group,~* pregnant and lactating females,~* long term steroid medication,~* smokers,~* alcoholics,~* immunocompromised individuals and~* those with history of antibiotic or periodontal therapy in preceding 6 months

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Garcinia Mangostana (Type: ACTIVE_COMPARATOR): The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
- Placebo gel (Type: PLACEBO_COMPARATOR): The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proliferating IH (target hemangioma) requiring systemic therapy anywhere on the body except on the diaper area with largest diameter of at least 1.5 cm~Exclusion Criteria:~- The patient presents with one or more of the following medical conditions: Congenital hemangioma; Kasabach-Merritt syndrome; bronchial asthma; bronchospasm; hypoglycaemia (\< 40 mg/dl or at risk); untreated phaeochromocytoma; hypotension (\< 50/30 mmHg); second or third degree heart block; cardiogenic shock; metabolic acidosis; bradycardia (\< 80 bpm); severe peripheral arterial circulatory disturbances; Raynaud's phenomenon; sick sinus syndrome; uncontrolled heart failure or Prinzmetal's angina; documented PHACES syndrome with central nervous system involvement~* The patient has previously been treated for IH, including any surgical and/or medical procedures (e.g. laser therapy)~* The patient is known to have a hypersensitivity to propranolol and/or any other beta-blockers~* One or more of the following types of IH are present:~  * Life-threatening IH~ * Function-threatening IH (e.g. those causing impairment of vision, respiratory compromise caused by airway lesions, etc.)~ * Ulcerated IH (whatever the localisation) with pain and lack of response to simple wound care measures~* The patient was born prematurely and has not yet reached his/her term equivalent age (e.g. an infant born 2 months prematurely cannot be included before the age of 2 months)~* LVEF (left ventricular systolic function) ≤40% and/or cardiomyopathy and/or hereditary arrhythmia disorder

- Gender: ALL
- Minimum Age: 35 Days
- Maximum Age: 150 Days
- Healthy Volunteers: f

Study Arms:
- Propranolol oral solution (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete